Manufacturer of Palbociclib

Palbociclib (Palbociclib) is in clinical development by Pfizer and is currently in Phase III for metastatic breast cancer. Palbociclib is a pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with high anti-tumor activity. It is formulated as hard gelatin capsules, tablets and film-coated tablets for the oral route of administration.

Palbociclib combined with letrozole for the treatment of estrogen receptor(ER)-positive, human epidermal growth factor receptor 2 As initial endocrine therapy for metastatic disease in postmenopausal women with (HER2)-negative advanced breast cancer, it can also be used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer, in combination with fulvestrant for endocrine therapy. For the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer in women with disease progression after endocrine therapy, in combination with an aromatase inhibitor, and in combination with fulvestrant in women who have previously received endocrine therapy.

The original drug of palbociclib has been launched in China and has entered the scope of Class B medical insurance, but reimbursement is limited to patients who meet the indications. The price of each box may be more than more than 4,000 yuan. The price of palbociclib's original drug, 125mg*21 capsules, per box sold overseas may be more than RMB 10,000 (the price may fluctuate due to exchange rates). There are also generic palbociclib drugs produced in other countries. The price of 125mg*21 tablets produced by a Bangladeshi pharmaceutical factory may be around a few hundred yuan per box (the price may fluctuate due to the exchange rate). The price is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.